Camrelizumab exhibits dual specificity implications for antitumor immunity
Open Access
- 18 March 2026
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (4) , 41-51
Abstract
Introduction. Camrelizumab is a high-affinity monoclonal antibody targeting programmed cell death protein 1 (PD-1) that has demonstrated strong clinical activity across multiple solid tumors. Emerging evidence suggests that camrelizumab can bind not only PD-1 but also the stress-induced ligand ULBP2 which activates natural killer (NK) and CD8+-T cells. Aim. To experimentally verify specific camrelizumab binding to ULBP2 (in contrast to reference anti-PD-1 antibodies pembrolizumab, nivolumab, and prolgolimab), compare anti-PD-1 antibodies binding profiles, and explore the potential immunological implications of camrelizumab dual specificity to PD-1 and ULBP2 in the context of antitumor immune response. Materials and methods. Binding interactions between ULBP2 and the four anti-PD-1 antibodies (camrelizumab, pembrolizumab, nivolumab, and prolgolimab) were assessed using surface plasmon resonance and flow cytometry. Results. Among all the tested antibodies, only camrelizumab exhibited specific binding to ULBP2 (KD (equilibrium dissociation constant) = 2.79 × 10–7 M). This interaction was confirmed by two independent methods. Conclusion. Camrelizumab displays a unique dual specificity for PD-1 and ULBP2 maintaining activity of effector lymphocytes and potentially decreases the dependence of therapy efficacy of PD-1 ligand (PD-L1) expression level. These findings expand our understanding of the biological features of camrelizumab and support its potential as an immunomodulator with broadened activity.Keywords
This publication has 22 references indexed in Scilit:
- ULBP2 promotes progression of head and neck squamous cell carcinoma by modulating MAPK signaling pathwayJournal of Stomatology Oral and Maxillofacial Surgery, 2024
- Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trialMed, 2024
- 62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trialESMO Open, 2024
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyThe Lancet, 2023
- Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 TrialJournal of Thoracic Oncology, 2023
- Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialJournal of Thoracic Oncology, 2022
- Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialThe Lancet Oncology, 2021
- Camrelizumab: First Global ApprovalDrugs, 2019
- The NKG2D receptor: sensing stressed cellsTrends in Molecular Medicine, 2008
- Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expressionCellular Immunology, 2006